Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | BCL2 | P10415 | 13/20 | 0.44 |
| ▸ | BAK1 | Q16611 | 7/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 8/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126392 | 1.00 | DRD2 (0.51) | DRD2BCL2BAK1HTR7DRD4 | |
| Hydrochloric Acid SCHEMBL5132534 | 0.99 | DRD2 (0.50) | DRD2BCL2BAK1HTR7DRD4 | |
| SCHEMBL3822802 | 0.91 | DRD2 (0.45) | DRD2BCL2BAK1DRD4 | |
| Hydrochloric Acid SCHEMBL5128653 | 0.90 | DRD2 (0.44) | DRD2BCL2BAK1DRD4 | |
| Hydrochloric Acid SCHEMBL5123855 | 0.90 | DRD2 (0.44) | DRD2BCL2BAK1DRD4 | |
| SCHEMBL3815352 | 0.89 | DRD2 (0.42) | DRD2BCL2BAK1HTR7DRD4 | |
| SCHEMBL5129265 | 0.85 | BCL2 (0.45) | DRD2BCL2BAK1HTR7DRD4 | |
| Hydrochloric Acid SCHEMBL5130057 | 0.83 | DRD2 (0.48) | DRD2 | |
| Hydrochloric Acid SCHEMBL5127297 | 0.83 | DRD2 (0.48) | DRD2 | |
| SCHEMBL5130211 | 0.82 | HTR7 (0.41) | DRD2BCL2BAK1HTR7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | DRD2 2487/4885BCL2 2/4885BAK1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.